EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The parkin V380L variant is a genetic modifier of Machado–Joseph disease with impact on mitophagy

Jonasz J Weber iD, Leah Czisch, Priscila Pereira Sena iD, Florian Fath iD, Chrisovalantou Huridou iD, Natasa Schwarz iD, Rana D Incebacak Eltemur iD, Anna Würth, Daniel Weishäupl, Miriam Döcker, Gunnar Blumenstock, Sandra Martins iD und 17 weitere

Acta Neuropathologica · 01.08.2024 · 148 (1)

DOI: 10.1007/s00401-024-02762-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 01.08.2024. Verfasst von Jonasz J Weber und 28 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076, Tübingen, Germany. Hauptthemen laut MEDLINE: Machado-Joseph Disease, Ubiquitin-Protein Ligases, Mitophagy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Ciência sem Fronteiras, European Reference Network for Rare Neurological Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Machado–Joseph disease (MJD) is an autosomal dominant neurodegenerative spinocerebellar ataxia caused by a polyglutamine-coding CAG repeat expansion in the ATXN3 gene. While the CAG length correlates negatively with the age at onset, it accounts for approximately 50% of its variability only. Despite larger efforts in identifying contributing genetic factors, candidate genes with a robust and plausible impact on the molecular pathogenesis of MJD are scarce. Therefore, we analysed missense single nucleotide polymorphism variants in the PRKN gene encoding the Parkinson's disease-associated E3 ubiquitin ligase parkin, which is a well-described interaction partner of the MJD protein ataxin-3, a deubiquitinase. By performing a correlation analysis in the to-date largest MJD cohort of more than 900 individuals, we identified the V380L variant as a relevant factor, decreasing the age at onset by 3 years in homozygous carriers. Functional analysis in an MJD cell model demonstrated that parkin V380L did not modulate soluble or aggregate levels of ataxin-3 but reduced the interaction of the two proteins. Moreover, the presence of parkin V380L interfered with the execution of mitophagy—the autophagic removal of surplus or damaged mitochondria—thereby compromising cell viability. In summary, we identified the V380L variant in parkin as a genetic modifier of MJD, with negative repercussions on its molecular pathogenesis and disease age at onset.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Machado-Joseph DiseaseUbiquitin-Protein LigasesMitophagyHumansMaleFemaleMiddle AgedAdultPolymorphism, Single NucleotideAtaxin-3Age of OnsetRepressor Proteins

Stichwörter der Autor:innen

PRKNAggregationPolyglutamine diseaseSCA3SNPSpinocerebellar ataxia type 3

Substanzen

Ubiquitin-Protein Ligasesparkin proteinAtaxin-3ATXN3 protein, humanRepressor Proteins

Autor:innen und Institutionen

  • Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076, Tübingen, Germany.
  • Department of Human Genetics, Ruhr University Bochum, 44801, Bochum, Germany.
  • Department of Clinical Epidemiology and Applied Biometry, University of Tübingen, 72076, Tübingen, Germany.
  • i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135, Porto, Portugal.
  • IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, 4200-135, Porto, Portugal.
  • ICBAS School of Medicine and Biomedical Sciences, University of Porto, 4050-313, Porto, Portugal.

ORCID-Profile: Jonasz J Weber, Priscila Pereira Sena, Florian Fath, Chrisovalantou Huridou, Natasa Schwarz, Rana D Incebacak Eltemur, Sandra Martins, Jorge Sequeiros, Guy A Rouleau, Laura Bannach Jardim, Maria-Luiza Saraiva-Pereira, Marcondes C França, Carlos R Gordon, Mario R Cornejo-Olivas, Alexandra Durr, Alexis Brice, Peter Bauer, Ludger Schöls, Olaf Riess, Thorsten Schmidt

Förderung

  • Deutsche Forschungsgemeinschaft
  • Ciência sem Fronteiras
  • European Reference Network for Rare Neurological Diseases
  • Bundesministerium für Bildung und Forschung
  • European commission, FP6
  • Universitätsklinikum Tübingen

Zitieren

APA

Weber, J. J., Czisch, L., Pereira Sena, P., Fath, F., Huridou, C., Schwarz, N., Incebacak Eltemur, R. D., Würth, A., Weishäupl, D., Döcker, M., Blumenstock, G., Martins, S., Sequeiros, J., Rouleau, G. A., Jardim, L. B., Saraiva-Pereira, M. L., França, M. C., Gordon, C. R., Zaltzman, R., …, & Schmidt, T. (2024). The parkin V380L variant is a genetic modifier of Machado–Joseph disease with impact on mitophagy. Acta Neuropathologica, 148(1). https://doi.org/10.1007/s00401-024-02762-6

Vancouver

Weber JJ, Czisch L, Pereira Sena P, Fath F, Huridou C, Schwarz N, et al. The parkin V380L variant is a genetic modifier of Machado–Joseph disease with impact on mitophagy. Acta Neuropathologica. 2024;148(1). doi:10.1007/s00401-024-02762-6

BibTeX
@article{Weber2024,
  author = {Weber, Jonasz J and Czisch, Leah and Pereira Sena, Priscila and Fath, Florian and Huridou, Chrisovalantou and Schwarz, Natasa and Incebacak Eltemur, Rana D and Würth, Anna and Weishäupl, Daniel and Döcker, Miriam and Blumenstock, Gunnar and Martins, Sandra and Sequeiros, Jorge and Rouleau, Guy A and Jardim, Laura Bannach and Saraiva-Pereira, Maria-Luiza and França, Marcondes C and Gordon, Carlos R and Zaltzman, Roy and Cornejo-Olivas, Mario R and van de Warrenburg, Bart P C and Durr, Alexandra and Brice, Alexis and Bauer, Peter and Klockgether, Thomas and Schöls, Ludger and Riess, Olaf and EUROSCA Network, EUROSCA Network and Schmidt, Thorsten},
  title = {The parkin V380L variant is a genetic modifier of Machado–Joseph disease with impact on mitophagy},
  journal = {Acta Neuropathologica},
  year = {2024},
  volume = {148},
  number = {1},
  doi = {10.1007/s00401-024-02762-6}
}
Kostenlos starten →